Non-HDL-C

More documents

Recommendations

Info

TNT: Events in HDL-C and LDL-C Quintiles 16 14 5-year K-M incidence of MCVE (%) 12 10 8 6 4 2 0 1 (
New CV events in MI patients with normal cholesterol levels 80 75% New CV events (% Patients) 60 40 20 45% 0 HDL < 35 mg/dl HDL > 35 mg/dl AJC 2001; 88(suppl): 9N-13N
Page 1 and 2: Current Targets and Treatment Gaps
Page 3 and 4: Fasting and Nonfasting TG: Equally
Page 5 and 6: Role of Low HDL-C in Residual Cardi
Page 7 and 8: Association Between LDL-C, Non-HDL-
Page 9: CHD risk predicted by HDL and LDL i
Page 13 and 14: Percentage of patients reaching ADA
Page 15 and 16: IS THERE AN ASYMPTOTIC LIMIT FOR LD
Page 17 and 18: CAD risk can be reduced to a maximu
Page 19 and 20: Should both HDL-C and LDL- C be tar
Page 21: Should HDL Raising Be a Target for
Page 28 and 29: Recommendations for management of d
Page 30: NCEP ATPIII, AHA, and ADA: Recommen
Page 33 and 34: NCEP ATP III Guidelines (Cont.) If
Page 35 and 36: American Diabetes Association Stand
Page 37 and 38: Target Levels Risk Level Initiate t
Page 44 and 45: Conclusion Non pharmacological stra

Non-HDL-C

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?